Munich - Delayed Quote EUR

Iovance Biotherapeutics Inc (2LB.MU)

10.94

-0.05

(-0.50%)

At close: April 26 at 8:03 AM GMT+2

3 Millionaire-Maker Biotech Stocks

The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential.

Motley Fool yesterday

IOVA

VKTX

RXRX
20 Counties with the Highest Cancer Rates in the US

In this article, we will be taking a look at the 20 counties with the highest cancer rates in the US. If you do not want to learn about the global impact of cancer, head straight to the 5 Counties with the Highest Cancer Rates in the US. Confronting Cancer: Global Impact and Trends in […]

Insider Monkey yesterday

KYMR

IOVA
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting

Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileucel plus Pembrolizumab in Advanced Frontline MelanomaSAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that clinical data for lifileucel in combination with pembrolizuma

GlobeNewswire 2 days ago

IOVA
These Biotech Stocks Could Soar 120% and 295%, According to Wall Street

Catalysts lie ahead for both of these companies.

Motley Fool 5 days ago

IOVA

NVAX
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on April 18, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 79,310 shares of Iovance’s common stock to thirty-seven new,

GlobeNewswire 7 days ago

IOVA
Is Iovance Biotherapeutics Stock a Buy Now?

Let's find out if this biotech can keep up its recent momentum.

Motley Fool 9 days ago

IOVA
Market Sentiment Around Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) is possibly approaching a major achievement in its business, so we would...

Simply Wall St. 17 days ago

IOVA
Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why

Iovance (IOVA) surges on the recent FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.

Zacks 18 days ago

IOVA

LGNZZ

ANIP
Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics

These companies are in the early days of their growth stories.

Motley Fool 21 days ago

CRSP

IOVA
Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 28 days ago

IOVA

MNKD
2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street

Find out why investment banks up and down Wall Street have big expectations for these stocks.

Motley Fool last month

VKTX

IOVA
U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies

A proposed bill in Congress targets Chinese biotech businesses that play an important role in developing drugs.

The Wall Street Journal last month

MEDP

IOVA

LLY
Iovance Biotherapeutics (NASDAQ:IOVA) shareholders are still up 122% over 1 year despite pulling back 7.1% in the past week

Unless you borrow money to invest, the potential losses are limited. On the other hand, if you find a high quality...

Simply Wall St. last month

IOVA
7 Biotech Stocks Ready to Ride the Sector’s Resurgence

Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation. First, the hard data supports bullishness in biotech stocks. According to Grand View Research, the underlying global industry reached a valuation of $1.55 trillion last year. Moving forward, experts project that the sector will expand at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030. At the culmination point, the space may be worth $3.88 trillion. Second, a sector r

InvestorPlace last month

TECH

CNTA

CPRX
Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead

This company's growth story is about to get moving with gusto.

Motley Fool last month

IOVA

LLY
Billionaire Paul Tudor Jones and Insiders Love These 10 Stocks

In this article, we will take a detailed look at Billionaire Paul Tudor Jones and Insiders Love These 10 Stocks. For a quick overview of such stocks, read our article Billionaire Paul Tudor Jones and Insiders Love These 5 Stocks. In an interview given to the Palm Beach Civic Association in January 2024, billionaire Paul Tudor Jones said that […]

Insider Monkey last month

IOVA

AON

SRRK
1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17?

Its revenue is set to grow, and one of its trials is no longer paused.

Motley Fool last month

IOVA
Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst

With its first approval in hand, attention is now on the top line.

Motley Fool last month

IOVA
FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study

The FDA removes the clinical hold on Iovance's (IOVA) mid-stage study on LN-145 in certain NSCLC patients after reviewing the company's proposal for additional safety measures and monitoring.

Zacks last month

IOVA

PBYI

ADMA
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer

SAN CARLOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) lifted a partial clinical hold placed on the registrational IOV-LUN-202 trial investigating LN-145 TIL cell therapy in non-small cell lung cancer (NSCLC). In co

GlobeNewswire last month

IOVA

Performance Overview

Return	2LB.MU	S&P 500
YTD	+39.30%	+6.92%
1-Year	+110.77%	+25.26%
3-Year	-57.71%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Iovance Biotherapeutics Inc (2LB.MU)

3 Millionaire-Maker Biotech Stocks

20 Counties with the Highest Cancer Rates in the US

Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting

These Biotech Stocks Could Soar 120% and 295%, According to Wall Street

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Is Iovance Biotherapeutics Stock a Buy Now?

Market Sentiment Around Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why

Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics

Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?

2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street

U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies

Iovance Biotherapeutics (NASDAQ:IOVA) shareholders are still up 122% over 1 year despite pulling back 7.1% in the past week

7 Biotech Stocks Ready to Ride the Sector’s Resurgence

Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead

Billionaire Paul Tudor Jones and Insiders Love These 10 Stocks

1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17?

Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst

FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study

Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer

Performance Overview